Visfatin Levels Before and After Periodontal Treatment

Gingival Crevicular Fluid and Serum Levels of Visfatin in Periodontal Diseases Before and After Non-surgical Periodontal Treatment

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02615626

Acronym

Enrollment

Registered

2015-11-26

Start date

2012-05-31

Completion date

2014-01-31

Last updated

2015-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Periodontal Diseases

Keywords

Visfatin, GCF, serum, Non-surgical Periodontal Treatment.

Brief summary

The purpose of this study was to evaluate visfatin levels in different stages of periodontal diseases and health, moreover the effect of non-surgical periodontal therapy on visfatin levels in Gingival Crevicular Fluid (GCF) and Serum.

Detailed description

Total of 45 patients were divided into three groups based on their clinical and radiographical examination. Group 1 chronic periodontitis (n: 15), group 2 plaque induced gingivitis (n: 15) and group 3 Periodontal health (n: 15). GCF and serum samples were collected before treatment and 1, 3, 6 months after treatment and were assayed using enzyme linked immunosorbent assay kit.

Interventions

PROCEDURENon-surgical Periodontal Treatment.

Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

Group 1 Inclusion Criteria: * GI\>1, PPD≥5mm, CAL≥5mm with alveolar bone loss radiographically. * Systematically healthy patients Group 2 Inclusion Criteria: * No alveolar bone and attachment loss * Inflammation signs such as redness, edema and increased BOP levels, * GI≥2, PPD≤3mm, CAL≤3mm. * Systematically healthy patients Group 3 Inclusion Criteria: * No bone and attachment loss, * GI=0, PPD≤3mm, CAL≤3mm * Systematically healthy patients

Exclusion criteria

for all groups: * Aggressive Periodontitis, * Oral pathologies, * Patients with any other systemic diseases, * Pregnant women and those in the lactation period, * Patients with smoking habit and taking medication * Patients received periodontal therapy in last 6 months

Design outcomes

Primary

Measure	Time frame
Visfatin levels: Change after periodontal treatment both in serum and GCF	baseline, 1, 3 and 6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026